Jackson Hole Capital Partners LLC Has $2.81 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Jackson Hole Capital Partners LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 11.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 110,837 shares of the biopharmaceutical company's stock after purchasing an additional 11,828 shares during the quarter. Jackson Hole Capital Partners LLC's holdings in Pfizer were worth $2,809,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Providence Capital Advisors LLC boosted its stake in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after acquiring an additional 409 shares in the last quarter. William B. Walkup & Associates Inc. boosted its stake in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after acquiring an additional 454 shares in the last quarter. Members Trust Co boosted its stake in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 467 shares in the last quarter. Sutton Place Investors LLC boosted its stake in shares of Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after acquiring an additional 472 shares in the last quarter. Finally, Bellevue Group AG boosted its position in shares of Pfizer by 0.3% in the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after buying an additional 485 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on PFE. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Finally, HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.01 during trading on Thursday, reaching $25.37. The company's stock had a trading volume of 25,643,723 shares, compared to its average volume of 38,513,248. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The business's fifty day moving average price is $24.26 and its 200-day moving average price is $24.70. The firm has a market cap of $144.25 billion, a price-to-earnings ratio of 18.39, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.78%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.